Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib) - Study to immuneresponse in patients treated with a tki

niversitair Medisch Centrum Sint Radboud0 sites75 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

last year

Study Type

Observational invasive

Sponsor

niversitair Medisch Centrum Sint Radboud

•\- Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks, or patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
•\- Patients who are indicated for influenza vaccination and and have been summoned for this vaccination by their GP
•\- age \>\=18 years
•\- signed Informed Consent Form

•\- patients with an identified immunodeficiency disorder
•\- patients that have been treated with corticosteroids in the past 2 weeks or who are still using these (except for a short period \<10 days)
•\- patients that are treated with immunotherapy in the last year (ex. interferon\-alpha of IL\-2\) or who have received another form of targeted therapy (ex. bevacizumab).
•\- patients with symptoms of influenza at the time of vaccination
•\- patient with an allergy for